

Advancing Psychiatric Practice Through the Science of Addiction


A Research Track From the
NATIONAL INSTITUTE ON DRUG ABUSE



AMERICAN PSYCHIATRIC ASSOCIATION

164th Annual Meeting
Honolulu, HI • May 14–18, 2011

NIDA NATIONAL INSTITUTE
ON DRUG ABUSE



AMERICAN PSYCHIATRIC ASSOCIATION ANNUAL MEETING

Honolulu, Hawaii • May 14–18, 2011

MISSION STATEMENT

The mission of the National Institute on Drug Abuse (NIDA) is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. This charge has two critical components. The first is strategic support and conduct of basic, clinical, and applied research across a broad range of disciplines, ranging from genetics and neurobiology to behavioral and social science. The second is ensuring the rapid and effective dissemination and use of research results to improve prevention and treatment, and inform policy.

EXHIBIT

A wide variety of materials are available at the NIDA exhibit, at Booth 1030, in the APA Exhibit Hall.

WEBSITE

Information about NIDA research, programs, and events is accessible through NIDA's website at www.drugabuse.gov.

SATURDAY, MAY 14

8:00 a.m.–11:00 a.m. **Symposium (Session #S4)**
Brain Mechanisms and Neuropsychiatry in Smoking Cessation
Hawaii Convention Center—Room 317A/B, Level 3

Co-Chairs: Geetha Subramaniam, M.D.
National Institute on Drug Abuse

Steven Grant, Ph.D.
National Institute on Drug Abuse

Presenters: Amy Janes, Ph.D.
McLean Hospital
*Brain Functional Magnetic Resonance Imaging Reactivity and
Attentional Bias in Tobacco Abstinence*

Richard Yi, Ph.D.
University of Maryland, College Park
Impulsivity in Smoking Cessation

Benjamin Toll, Ph.D.
Yale University School of Medicine
*Naltrexone in Supplementing Nicotine Replacement Therapy
for Smokers*

Laura MacPherson, Ph.D.
University of Maryland, College Park
*Behavioral Activation in Depressed Smokers Receiving Nicotine
Replacement Therapy*

Discussant: Tony George, M.D.
University of Toronto

SUNDAY, MAY 15

8:00 a.m.–11:00 a.m. **Symposium (Session #S13)**
**Decision Making and Addictions: Neurobiology and
Treatment Implications**

Hawaii Convention Center—Room 324, Level 3

Co-Chairs: Ivan Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Frederick Moeller, M.D.
The University of Texas Health Science Center

Presenters: Catharine Winstanley, Ph.D.
University of British Columbia
Basic Neurobiology of Decision Making

Scott Lane, Ph.D.
The University of Texas Health Science Center
The Impact of Drugs of Abuse on Decision Making

Warren Bickel, Ph.D.
Virginia Tech Carilion Research Institute
*Neuro-Cognitive and Behavioral Interventions to Improve Addict
Decision Making*

Frederick Moeller, M.D.
The University of Texas Health Science Center
*Pharmacotherapies for Drug Addiction Aiming at Improving
Decision Making*

Discussant: Antoine Bechara, Ph.D.
University of Southern California

MONDAY, MAY 16

8:00 a.m.–11:00 a.m. Symposium (Session #S36)

The Shrinking Psychotherapeutic Pipeline: Why Has the Spigot Been Turned Off?

Hawaii Convention Center—Room 316A, Level 3

Co-Chairs: Ivan Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Bruce Cuthbert, Ph.D.
National Institute of Mental Health

Presenters: Irwin Lucki, Ph.D.
University of Pennsylvania
Increasing the Validity of Animal Models of Depression by Genetic–Environment Interactions

David Michelson, M.D.
Merck and Company
New Drugs to No Drugs: Antidepressants and Drug Discovery/Development

Mark Geyer, Ph.D.
University of California, San Diego
Cross-Species Tests for Cognition Enhancement in Schizophrenia

Lon Schneider, M.D.
University of Southern California Keck School of Medicine
Alzheimer’s Disease Clinical Trial Failures: Ineffective Drugs or Flawed Clinical Trials?

Discussant: Steven Paul, M.D.
Cornell University

10:00 a.m.–11:30 a.m. Frontiers of Science Lecture (Session #L17)

Transforming Clinical Outcomes in Addiction

Hawaii Convention Center—Kalakaua Ballroom, Level 4

Speaker: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse

10:00 a.m.–11:30 a.m. **Workshop (Session #W68)**

Does the Brain Ever Recover From Drug Addiction?

Hawaii Convention Center—Room 319A/B, Level 3

Chair: Steven Grant, Ph.D.

National Institute on Drug Abuse

Presenters: Jay Nierenberg, M.D., Ph.D.

Nathan S. Klein Institute for Psychiatric Research

Diana Martinez, M.D.

Columbia University

George Fein, Ph.D.

Neurobehavioral Research, Inc.

Marc Potenza, M.D., Ph.D.

Yale University

12:00 p.m.–1:30 p.m. **Forum (Session #F04)**

Health Reform: Transforming Addiction Services in the United States

Hawaii Convention Center—Room 310, Level 3

Co-Chairs: Nora D. Volkow, M.D.

Director, National Institute on Drug Abuse

Wilson Compton, M.D., M.P.E.

National Institute on Drug Abuse

Presenters: Thomas McLellan, Ph.D.

University of Pennsylvania

Overview of Health Reform and Implications for Addiction Services

H. Westley Clark, M.D., J.D., M.P.H.

Substance Abuse and Mental Health

Services Administration

Electronic Health Records and Privacy Concerns

TUESDAY, MAY 17

8:00 a.m.–11:00 a.m. Symposium (Session #S61)
Update on the Treatment of Comorbid Opioid Addiction and Chronic Pain

Hawaii Convention Center—Room 318, Level 3

Chair: Will M. Aklin, Ph.D.
National Institute on Drug Abuse

Presenters: Sean Mackey, M.D., Ph.D.
Stanford University
Update on the Treatment of Acute and Chronic Pain in the Patient With a History of Addiction

Ian Carroll, M.D.
Stanford University
A Prospective, Longitudinal, Observational Cohort Study of Pain Duration in Post-Surgical Patients

Declan Barry, Ph.D.
Yale University
Cognitive–Behavioral Treatment for Co-occurring Chronic Pain and Opioid Dependence

Roger Weiss, M.D.
Harvard University
Pain and Prescription Opioid Dependence: Secondary Outcomes From NIDA Clinical Trials Network's Prescription Opioid Addiction Treatment Study

Jennifer Potter, Ph.D.
The University of Texas Health Science Center
Co-occurring Chronic Pain and Opioid Addiction: Is There a Role for Integrated Treatment?

8:00 a.m.–11:00 a.m. Symposium (Session #S63)
**Marijuana and Psychosis: Epidemiology, Neuroscience, and
Clinical Perspectives**

Hawaii Convention Center—Room 324, Level 3

Co-Chairs: Wilson Compton, M.D., M.P.E.
National Institute on Drug Abuse

Steven Grant, Ph.D.
National Institute on Drug Abuse

Presenters: David Fergusson, Ph.D.
University of Otago, New Zealand
Cannabis Use and Psychosis: Is There a Causal Link?

Nathan Gillespie, Ph.D.
Virginia Commonwealth University
*Exploring the Genetic and Environmental Association Between
Cannabis Use and Psychosis*

Dean Wong, M.D., Ph.D.
Johns Hopkins University
*Imaging Cannabinoid Receptors in Patients With Schizophrenia
Using PET*


Joseph Cheer, Ph.D.
University of Maryland
*Endogenous Cannabinoids and the Neurobiological Control of
Mental Illness*

Discussant: Deepak Cyril D'Souza, M.D.
Yale University

HAWAII CONVENTION CENTER LEVEL 3 MEETING ROOMS



HAWAII CONVENTION CENTER LEVEL 4 MEETING ROOMS



American Psychiatric Association Annual Meeting

SYNERGY ENTERPRISES, INC.
8757 GEORGIA AVENUE, SUITE 1440
SILVER SPRING, MD 20910



NATIONAL INSTITUTES OF HEALTH
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES